Trial record 2 of 2 for:    Lingo-1

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT01244139
First received: November 18, 2010
Last updated: November 8, 2012
Last verified: November 2012

November 18, 2010
November 8, 2012
October 2010
April 2012   (final data collection date for primary outcome measure)
  • Evaluate safety and tolerability profile of two IV infusions of BIIB033 in subjects with MS [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Identify incidence and types of adverse events [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • The incidence of serious adverse events [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Changes from baseline in clinical lab assessments and vital signs [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Changes form baseline in other safety measures: physical and neurological examinations, brain MRIs, and ECGs [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01244139 on ClinicalTrials.gov Archive Site
  • Assess the repeat-dose serum PK profile of BIIB033 [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Assess the repeat-dose immunogenicity of BIIB033 [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Measure the concentration of BIIB033 in the cerebrospinal fluid [ Time Frame: At specified timepoints in the study ] [ Designated as safety issue: Yes ]
  • Explore potential biomarkers of BIIB033 activity in the periphery and in the central nervous system [ Time Frame: At specified timepoints in the study ] [ Designated as safety issue: No ]
  • Assess the repaeat-dose serum PK profile of BIIB033 [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Assess the repeat-dose immunogenicity of BIIB033 [ Time Frame: For duration of study / 6 months ] [ Designated as safety issue: Yes ]
  • Measure the concentration of BIIB033 in the cerebrospinal fluid [ Time Frame: At specified timepoints in the study ] [ Designated as safety issue: Yes ]
  • Explore potential biomarkers of BIIB033 activity in the periphery and in the central nervous system [ Time Frame: At specified timepoints in the study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis

The main purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic profile of two intravenous infusions of BIIB033 administered two weeks apart in subjects with MS.

Approximately 42 MS subjects are planned to be enrolled in the study in 7 separate groups (i.e., 6 subjects per group). Each subsequent group will be administered a higher dose of BIIB033. Before a higher dose group is allowed to start, a Drug Safety Review Committee will review all safety data from previous groups enrolled, as well as data from another study where BIIB033 is being administered to healthy volunteers (215HV101).

BIIB033 is a protein that acts on certain types of brain cells by blocking the function of another protein called LINGO-1. It is believed that LINGO-1 is one of the reasons why nerves in the brain of patients with MS do not repair well. It is thought BIIB033 may improve MS by repairing damaged nerve tissue. LINGO-1 is also present in the brain of healthy people.

Subjects will take part in the 215MS101 study for up to 28 weeks. This includes a 4-week screening period, a 2 week treatment period in which 2 doses of BIIB033 are given, and a post-dosing safety follow up period of up to 22 weeks (depending on dose cohort).

The study tests vary at each of the individual visits and may include:

medical history evaluation, height and weight assessment, physical examination, neurological examination, vital signs assessment (pulse, respiratory rate, blood pressure, and temperature), MS performance score, electrocardiogram, cardiac monitoring, routine blood and urine tests, drug concentration testing of the blood, hepatitis and HIV tests, blood clotting tests, brain MRI scan, lumbar puncture, and drugs of abuse screen and pregnancy test.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis
  • Drug: BIIB033
    IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
  • Drug: Placebo
    IV infusion dummy drug
  • Experimental: Active study drug
    Treatment
    Intervention: Drug: BIIB033
  • Experimental: Comparator
    Dummy drug
    Intervention: Drug: Placebo
Boyd A, Zhang H, Williams A. Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol. 2013 Jun;125(6):841-59. doi: 10.1007/s00401-013-1112-y. Epub 2013 Apr 18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
47
April 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Give informed consnet
  • Aged 18 to 60 years
  • Have relapsing remitting MS or secondary progressive MS
  • EDSS score of 1 to 6 inclusive
  • Body mass index of 18 to 30 kg/m2
  • Commitment to use effective contraception 6 months after last dose of study drug Treatment with any interferon beta or glatiramer acetate is allowed to continue during the study as long as the initiation of treatment was at least 3 months and the dose is stable.

Key Exclusion Criteria:

  • Primary progressive MS
  • Any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, allergic or anaphylactic reactions or other major disease
  • Clinically significant lab value at screening outside of normal range
  • Clinically significant ECG abnormality
  • Contraindication to MRI scans or lumbar punctures
  • Plans to undergo elective surgery during study
  • An MS relapse that has not resolved within 30 days before screening
  • History or postive test result for Hepatitis B, C and HIV
  • Serious infections within 3 months prior to Day -1
  • Treatment with MS medication within 12 months prior to Day -1: natalizumab, daclizumab, azathioprine, methotrexate, iV immunoglobulin, plasmapheresis or mycophenolate motefil
  • Prior treatment with total lymphoid irradiation, T cell or T-cell receptor vaccination, alemtuzumab, mitoxantone, cyclophosphamide, rituximab, fingolimod.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01244139
215MS101
Yes
Biogen Idec
Biogen Idec
Not Provided
Not Provided
Biogen Idec
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP